StreetInsider.com News Articles

Jefferies Upgrades PTC Therapeutics (PTCT) to Buy, 'deep dive suggests Sephience should continue to beat expectations'

Wed, 27 May 2026 08:52:53 -0400

(Updated - May 27, 2026 8:52 AM EDT)

Jefferies analyst Faisal Khurshid upgraded PTC Therapeutics (NASDAQ: PTCT) from Hold to Buy with a price target of $85.00 (from $76.00).

The analyst comments "We upgrade PTCT to Buy and $85 PT as our deep dive suggests Sephience should continue to beat expectations and deliver 2026 and peak revs meaningfully above consensus. Our deep dive includes a new patient build model reconciling reported metrics, KOL insight, and a look at the PKU landscape. We like the setup here w/ beatable Sephience cons (peak $1.4B) and relatively low EV (~$4B). Beyond Sephience, we think votoplam

Jefferies Upgrades PTC Therapeutics (PTCT) to Buy, 'deep dive suggests Sephience should continue to beat expectations'

Wed, 27 May 2026 08:52:53 -0400

(Updated - May 27, 2026 8:52 AM EDT)

Jefferies analyst Faisal Khurshid upgraded PTC Therapeutics (NASDAQ: PTCT) from Hold to Buy with a price target of $85.00 (from $76.00).

Jefferies Upgrades PTC Therapeutics (PTCT) to Buy, 'deep dive suggests Sephience should continue to beat expectations'

Wed, 27 May 2026 08:52:53 -0400

(Updated - May 27, 2026 8:52 AM EDT)

Jefferies analyst Faisal Khurshid upgraded PTC Therapeutics (NASDAQ: PTCT) from Hold to Buy with a price target of $85.00 (from $76.00).

Jefferies Upgrades PTC Therapeutics (PTCT) to Buy, 'deep dive suggests Sephience should continue to beat expectations'

Wed, 27 May 2026 08:52:53 -0400

(Updated - May 27, 2026 8:52 AM EDT)

Jefferies analyst Faisal Khurshid upgraded PTC Therapeutics (NASDAQ: PTCT) from Hold to Buy with a price target of $85.00 (from $76.00).

Jefferies Upgrades PTC Therapeutics (PTCT) to Buy, 'deep dive suggests Sephience should continue to beat expectations'

Wed, 27 May 2026 08:52:53 -0400

(Updated - May 27, 2026 8:52 AM EDT)

Jefferies analyst Faisal Khurshid upgraded PTC Therapeutics (NASDAQ: PTCT) from Hold to Buy with a price target of $85.00 (from $76.00).

BofA on PTC Therapeutics (PTCT): 'See opportunity for >$2bn in global Sephience sales'

Wed, 20 May 2026 10:46:40 -0400

BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $93.00 price target on PTC Therapeutics (NASDAQ: PTCT).

The analyst comments "We hosted PTCT CEO, Dr. Matthew Klein, for a group dinner in NYC to discuss the Sephience launch, pipeline updates and the company’s business development strategy, with PTCT reiterating confidence in >$2bn global peak sales potential for Sephience. Management commentary remained consistent on the US Sephience launch, highlighting broad demand across all key patient segments with >90% of PKU COEs activated and continued expansion into non-specialty centers. Klein reiterated new scripts have stabilized around ~140 per month following an initial

Form 4 PTC THERAPEUTICS, INC. For: May 15 Filed by: Boulding Mark Elliott

Tue, 19 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260519/26522675.html

Form 4 PTC THERAPEUTICS, INC. For: May 15 Filed by: Boulding Mark Elliott

Tue, 19 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260519/26522675.html

Form 4 PTC THERAPEUTICS, INC. For: May 13 Filed by: Klein Matthew B.

Fri, 15 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260515/26507894.html

Form 4 PTC THERAPEUTICS, INC. For: May 13 Filed by: Klein Matthew B.

Fri, 15 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260515/26507894.html

Form SCHEDULE 13G/A PTC THERAPEUTICS, INC. Filed by: TORONTO DOMINION BANK

Fri, 15 May 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26503458.html

Form SCHEDULE 13G/A PTC THERAPEUTICS, INC. Filed by: TORONTO DOMINION BANK

Fri, 15 May 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260515/26503458.html

Form SCHEDULE 13G/A PTC THERAPEUTICS, INC. Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26502899.html

Form SCHEDULE 13G/A PTC THERAPEUTICS, INC. Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26502899.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501282.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501282.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Klein Matthew B.

Thu, 14 May 2026 15:10:00 -0400

si-local-file:///var/storage/secattach/20260514/26493933.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Klein Matthew B.

Thu, 14 May 2026 15:10:00 -0400

si-local-file:///var/storage/secattach/20260514/26493933.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Klein Matthew B.

Thu, 14 May 2026 12:44:00 -0400

si-local-file:///var/storage/secattach/20260514/26492829.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Klein Matthew B.

Thu, 14 May 2026 12:44:00 -0400

si-local-file:///var/storage/secattach/20260514/26492829.html

Form 4 PTC THERAPEUTICS, INC. For: May 08 Filed by: Boulding Mark Elliott

Tue, 12 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260512/26479406.html

Form 4 PTC THERAPEUTICS, INC. For: May 08 Filed by: Boulding Mark Elliott

Tue, 12 May 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260512/26479406.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Fri, 08 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260508/26461320.html

Form 144 PTC THERAPEUTICS, INC. Filed by: Boulding Mark Elliott

Fri, 08 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260508/26461320.html

PTC Therapeutics (PTCT) PT Raised to $94 at Morgan Stanley

Fri, 08 May 2026 08:10:29 -0400

Morgan Stanley analyst Jeffrey Hung raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $94.00 (from $92.00) while maintaining a Overweight rating.